| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Routes of administration | Intranasal |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
 COVID-19 portal |
INNA-051 is a COVID-19 vaccine candidate developed by Ena Respiratory. [1] [2]
iNCOVACC is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech, American company Precision Virologics and the Washington University School of Medicine in St Louis, Missouri, United States.
UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia, and Vaxxinity, Inc. It is a peptide vaccine.
A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.
Chinese Academy of Medical Sciences COVID-19 vaccine, or IMBCAMS COVID-19 vaccine, traded as Covidful, is a COVID-19 vaccine developed by Institute of Medical Biology, Chinese Academy of Medical Sciences.
Minhai COVID-19 vaccine, trademarked as KCONVAC, is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.
West China Hospital COVID-19 vaccine is a COVID-19 vaccine candidate developed by Jiangsu Province Centers for Disease Control and Prevention, West China Hospital and Sichuan University.
DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine candidate developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong.
Turkovac is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.
NDV-HXP-S is a COVID-19 vaccine candidate developed under the leadership of Peter Palese, Adolfo García-Sastre, and Florian Krammer at the Icahn School of Medicine at Mount Sinai.
Razi Cov Pars is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute.
COVID-19 vaccination in Japan started later than in most other major economies. The country has frequently been regarded as "slow" in its vaccination efforts.
COVI-VAC is a COVID-19 vaccine developed by Codagenix, Inc. In December 2020, COVI-VAC started a Phase I clinical trial, involving 48 participants. The trial was scheduled to complete in June 2021, with results to be reported by May 2022. On September 29, 2021, Codagenix presented positive phase 1 data for COVI-VAC at IDWEEK2021. Data indicates that COVI-VAC is well tolerated, with no significant adverse events reported and that administration of the intranasal vaccine was immunogenic and capable of blocking nasal replication of the virus with minimal viral shedding, recorded at levels lower than those likely to result in subsequent transmission of COVID-19. Furthermore, COVI-VAC was shown to stimulate both serum and mucosal antibody immune responses.
COVAX-19 is the result of a collaboration between Vaxine and CinnaGen, a private company with operations in the Middle East. COVAX-19 is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine. It is under clinical trial in collaboration with the Iranian company CinnaGen.
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:
Noora is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in collaboration with Plasma Darman Sarv Sepid Co. in Iran.
202-CoV is a COVID-19 vaccine candidate developed by Shanghai Zerun Biotechnology Co., Ltd., Walvax Biotech. It is one of several candidates under development by Walvax.
S-268019-b is a protein subunit COVID-19 vaccine candidate developed by Shionogi.
Stemirna COVID-19 vaccine is a COVID-19 vaccine candidate developed by Stemirna Therapeutics.
ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic.
 | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
